AFINITOR (everolimus), tyrosine kinase inhibitor

High clinical benefit but no proven clinical added value for the current treatment of progressive, non-functional, well-differentiated, non-resectable or metastatic gastrointestinal neuroendocrine tumours in adults

• AFINITOR has been granted a marketing authorisation for the treatment of progressive, non-functional, well-differentiated (Grade 1 or 2), non-resectable or metastatic gastrointestinal or pulmonary neuroendocrine tumours (NETs) in adults.

• A gain in progression-free survival versus placebo has been demonstrated, though there is no proven benefit in terms of overall survival or quality of life.

• Treatment discontinuation due to adverse events has been observed in almost one third of patients.

• No data versus recommended therapeutic alternatives are available for certain clinical gastrointestinal NET scenarios.